Literature DB >> 10628765

Risk factors for cancer in renal transplant recipients.

E Danpanich1, B L Kasiske.   

Abstract

BACKGROUND: Cancer continues to be an important cause of morbidity and mortality after renal transplantation. Unfortunately, risk factors for cancer have not been well defined.
METHODS: We examined risk factors for invasive, life-threatening malignancies among 1500 renal transplant recipients. Both univariate and multivariate Cox proportional hazards analyses were used.
RESULTS: There were 87 tumors in 88 patients. Actuarial survival free of cancer was 95.9% at 5 years, 92.3% at 10 years, 86.6% at 15 years, and 82.6% at 20 years. Among multiple possible risk factors, the adjusted, relative risk attributable to age at transplantation (compared to age <45 years) was 2.00 (95% confidence interval: 1.21-3.30, P = 0.007) for age > or =45 and <60 years (29.1% of total were in this age range), and 3.81 (95% confidence interval: 2.05-7.06, P<0.001) for age > or =60 years (11.6%). The relative risk attributable to pretransplant splenectomy (47.8%, now large abandoned) was 1.87 (95% confidence interval: 1.12-3.12, P = 0.016). Patients with renal disease from type 1 diabetes had a lower risk of cancer, 0.19 (95% confidence interval: 0.05-0.08, P = 0.015). A history of invasive cancer pretransplant (2.5%) increased the risk of posttransplant cancer to 2.38 (95% confidence interval: 1.18-4.83, P = 0.015). Cigarette smoking was also associated with an increased risk, with each 10 pack-years smoked at transplant increasing the risk of cancer by 1.12 (1.02-1.21, P = 0.016). The era when transplantation occurred, the type of prophylactic immunosuppression used, the occurrence of acute rejection, or its treatment did not alter the risk of cancer.
CONCLUSIONS: The risk of cancer continues to increase 15-20 years after transplantation. The identification of splenectomy as a new risk factor, even several years after this immunosuppression strategy has been abandoned, demonstrates that the risk of immunosuppression may take years to become manifest. Efforts to reduce immunosuppression, particularly for patients > or =45 years of age at transplant, along with a greater effort to discourage cigarette smoking, may help reduce the risk of cancer after renal transplantation. cer in a cohort of patients with long-term follow-up. Although this is a retrospective study, the ongoing, continuous follow-up of these patients has made it possible to accurately assess the incidence of invasive malignancy.

Entities:  

Mesh:

Year:  1999        PMID: 10628765     DOI: 10.1097/00007890-199912270-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  18 in total

1.  The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation.

Authors:  Shelly Lichtenberg; Ruth Rahamimov; Hefziba Green; Benjamin D Fox; Eytan Mor; Uzi Gafter; Avry Chagnac; Benaya Rozen-Zvi
Journal:  Eur J Clin Pharmacol       Date:  2017-03-24       Impact factor: 2.953

2.  De novo papillary carcinoma in a renal allograft: the pros and cons of immunosuppression.

Authors:  Rachelle Asciak; Jesmar Buttigieg; Louis Buhagiar
Journal:  CEN Case Rep       Date:  2015-11-02

3.  De novo malignancy post-liver transplantation: a single center, population controlled study.

Authors:  Hemant Chatrath; Kenneth Berman; Raj Vuppalanchi; James Slaven; Paul Kwo; A Joseph Tector; Naga Chalasani; Marwan Ghabril
Journal:  Clin Transplant       Date:  2013-06-30       Impact factor: 2.863

4.  Tobacco smoke-induced immunologic changes may contribute to oral carcinogenesis.

Authors:  Michael Schierl; Daxesh Patel; Wanhong Ding; Amit Kochhar; Katayun Adhami; Xi Kathy Zhou; Andrew J Dannenberg; Richard D Granstein
Journal:  J Investig Med       Date:  2014-02       Impact factor: 2.895

Review 5.  Renal transplantation in the elderly.

Authors:  Ramesh Saxena; Xueqing Yu; Mauricio Giraldo; Juan Arenas; Miguel Vazquez; Christopher Y Lu; Nosratola D Vaziri; Fred G Silva; Xin J Zhou
Journal:  Int Urol Nephrol       Date:  2008-11-07       Impact factor: 2.370

Review 6.  Incidence, risk factors and outcomes of de novo malignancies post liver transplantation.

Authors:  Pavan Kedar Mukthinuthalapati; Raghavender Gotur; Marwan Ghabril
Journal:  World J Hepatol       Date:  2016-04-28

Review 7.  Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.

Authors:  Roberto Marcén
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

Review 8.  Immunosenescence and organ transplantation.

Authors:  Timm Heinbokel; Abdallah Elkhal; Guangxiang Liu; Karoline Edtinger; Stefan G Tullius
Journal:  Transplant Rev (Orlando)       Date:  2013-04-30       Impact factor: 3.943

Review 9.  ABO incompatible renal transplants: Good or bad?

Authors:  Masaki Muramatsu; Hector Daniel Gonzalez; Roberto Cacciola; Atsushi Aikawa; Magdi M Yaqoob; Carmelo Puliatti
Journal:  World J Transplant       Date:  2014-03-24

Review 10.  Drug therapy in transplant recipients: special considerations in the elderly with comorbid conditions.

Authors:  José F Bernardo; Jerry McCauley
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.